Our GSEA enrichment analysis results indicate that PID1 may be associated with metabolic pathways, particularly in galactose and glucose metabolism, suggests that targeting these processes may alleviate hyperglycemia-related complications, ultimately benefiting patient outcomes (57). This evidence concerns the gene PID1 and Hyperglycemia.